SPOTLIGHTS

Torchdata has been our choice since 2023 March, in Prescient-LM — where I have been training LLMs. It was great! It was somewhat difficult to use sometimes, it didn’t have full documentation, etc, but it worked when it worked.

Read the blog summary of Nathan C. Frey and Dan Berenberg's ICLR 2024 Outstanding Paper Award Winner, "Protein Discovery with Discrete Walk-Jump Sampling." 

In a recent study, our scientists revealed new insights into the regulation of NINJ1, a membrane protein responsible for cell membrane rupture during cell death.

This prestigious recognition highlights Anwesha Dey's exceptional contributions to biomedical science and her commitment to advancing science, innovation, and health equity.

A boost spotlight highlights content that already exists somewhere on the internet.

A native spotlight is a new, short-form post that lives directly on gene.com.

Mauris dapibus purus vel eros egestas suscipit. Vivamus dignissim urna quis gravida pellentesque. Vivamus vulputate metus sed lacus porttitor, ut rutrum quam posuere. Aenean tristique mollis tempus. Aliquam a dignissim risus, nec lobortis arcu. Nunc consequat neque in velit imperdiet.

On October 10, 2024, the FDA approved ItovebiTM (inavolisib) in combination with palbociclib and fulvestrant, a new first-line treatment option for people with HR+, HER2-, PIK3CA-mutated metastatic breast cancer, one of the most commonly mutated genes in metastatic breast cancer.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Phasellus ac leo eget massa porta auctor. Sed efficitur ante purus, eget gravida ipsum rutrum mollis. Nulla tempor lacinia euismod. Proin justo sapien, dapibus a auctor eget, maximus quis nibh. Cras in hendrerit nisi. Ut non dictum nibh.

At this year’s American Academy of Ophthalmology meeting, we are presenting results from the Phase IV Elevatum study of our bispecific antibody in underrepresented communities at higher risk of developing diabetic macular edema. Follow #AAO2024.